SARS-CoV-2 nucleocapsid protein MHC Class I-restricted epitopes (SARS-CoV-2 N protein MHC-I epitopes)

The SARS-CoV-2 nucleocapsid (N) protein is a highly conserved and abundantly expressed structural protein essential for viral RNA packaging and assembly (UniProt P0DTC9). MHC Class I-restricted epitopes of the N protein are short peptide fragments, typically 8-11 amino acids in length, that are processed intracellularly and presented on the surface of infected cells by Major Histocompatibility Complex (MHC) Class I molecules (Grifoni et al., Cell, 2020). These epitopes are recognized by CD8+ cytotoxic T lymphocytes (CTLs), which play a critical role in clearing the virus by killing infected cells and providing long-term immunological memory (Le Bert et al., Nature, 2020). Unlike the Spike protein, the N protein is less prone to mutations, making its MHC-I epitopes attractive targets for universal COVID-19 vaccines and T-cell-based immunotherapies that aim to provide broad protection against emerging variants (Saini et al., Science Immunology, 2021). Therapeutic strategies focusing on these epitopes often involve multi-antigen vaccine platforms or peptide-based vaccines designed to elicit robust cellular immunity across diverse populations (IEDB). Clinical monitoring of responses to these epitopes often involves measuring interferon-gamma production or using MHC multimers to quantify epitope-specific T-cell populations. Overall, these epitopes represent a vital component of the host's ability to control SARS-CoV-2 infection and are a focal point for developing durable, variant-resistant medical countermeasures.

Other names

SARS-CoV-2 N protein CD8+ T-cell epitopesNucleocapsid MHC-I peptidesSARS-CoV-2 nucleoprotein MHC-I epitopesSARS-CoV-2 N protein cytotoxic T-cell epitopes

Activation of CD8+ cytotoxic T lymphocytes through the presentation of viral peptide fragments on MHC Class I molecules, leading to the targeted destruction of infected cells (PubMed: 32473127).